Demonstrating the utility of the ex vivo murine mycobacterial growth inhibition assay (MGIA) for high-throughput screening of tuberculosis vaccine candidates against multiple Mycobacterium tuberculosis complex strains
<p>Human tuberculosis (TB) is caused by various members of the <em>Mycobacterium tuberculosis</em> (Mtb) complex. Differences in host response to infection have been reported, illustrative of a need to evaluate efficacy of novel vaccine candidates against multiple...
Main Authors: | Painter, H, Willcocks, S, Zelmer, A, Reljic, R, Tanner, R, Fletcher, H |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2024
|
Similar Items
-
Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA)
by: Tanner, R, et al.
Published: (2021) -
Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells
by: Painter, H, et al.
Published: (2020) -
Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells
by: Hannah Painter, et al.
Published: (2020-02-01) -
The cross-species mycobacterial growth inhibition assay (MGIA) project 2010-2014
by: Brennan, M, et al.
Published: (2017) -
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
by: Pepponi, I, et al.
Published: (2017)